Bladder Carcinoma — Trials

Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 141
Recruiting: 74
Ph III recruiting: 14
Growth YoY: +6.5%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 48.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (49)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03266900	A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival(RESECT)	terminated	Early Phase 1	2	University Health Network, TorontoOTHER	1	Apr 20, 2022	clinicaltrials
NCT01245660	A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD)	terminated	Early Phase 1	3	University Hospital, BordeauxOTHER